Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Development of a predictive prognostic rule for early assessment of COVID-19 patients in primary care settings

Angel Vila-Corcoles\textsuperscript{a,b}, Eva Satue-Gracia\textsuperscript{a,b}, Angel Vila-Rovira\textsuperscript{b}, Cinta de Diego-Cabanes\textsuperscript{a}, Maria Jose Forcadell-Peris\textsuperscript{a}, Olga Ochoa-Gondar\textsuperscript{a,b,*}

\textsuperscript{a} Primary Care Department Camp de Tarragona, Institut Catala de la Salut, Tarragona, Spain
\textsuperscript{b} Universitary Institute of Primary Care Research IDIAP Jordi Gol, Barcelona, Spain

Received 8 February 2021; accepted 15 April 2021
Available online 28 May 2021

KEYWORDS
COVID-19;
Comorbidities;
Symptoms;
Mortality;
Prognosis

Abstract

Objective: To investigate possible early prognostic factors among middle-aged and older adult and explore prognostic rules stratifying risk of patients.

Design: Community-based retrospective cohort.

Setting: Primary Health Care Tarragona region.

Participants: 282 community-dwelling symptomatic patients $\geq$50 years with laboratory-confirmed COVID-19 (hospitalised and/or outpatient) during March–June 2020 in Tarragona (Southern Catalonia, Spain).

Main outcome measurements: Relationship between demographics, pre-existing comorbidities and early symptomatology (first 5-days) and risk of suffering critical outcome (ICU-admission/death) across clinical course was evaluated by logistic regression analyses, and simple predictive models were developed.

Results: Of the 282 cases (mean age: 65.9 years; 140 men), 154 (54.6%) were hospitalised (30 ICU-admitted) and 45 (16%) deceased. Median time follow-up in clinical course was 31 days (range: 30–150) for survivors and 14 days (range: 1–81) for deceased patients. In crude analyses, increasing age, male sex, some comorbidities (renal, respiratory or cardiac disease, diabetes and hypertension) and symptoms (confusion, dyspnoea) were associated with an increased risk to suffer critical outcome, whereas other symptoms (rinorrea, myalgia, headache, anosmia/disgeusia) were related with reduced risk. After multivariable-adjustment only age/years (OR: 1.04; 95% CI: 1.01–1.07; p = 0.004), confusion (OR: 5.33; 95% CI: 1.54–18.48; p = 0.008), dyspnoea (OR: 5.41; 95% CI: 2.74–10.69; p < 0.001) and myalgias (OR: 0.30; 95% CI: 0.10–0.93; p = 0.038) remained significantly associated with increased or reduced risk. A proposed CD65-M prognostic rule (acronym of above mentioned 4 variables) showed a good correlation with the risk of suffering critical outcome (area under ROC curve: 0.828; 95% CI: 0.774–0.882).

* Corresponding author.
E-mail address: ochoa.tarte.ics@gencat.cat (O. Ochoa-Gondar).

https://doi.org/10.1016/j.aprim.2021.102118

0212-6567/© 2021 The Authors. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
**PALABRAS CLAVE**

COVID-19; Comorbilidades; Mortalidad; Síntomas; Pronóstico

---

**Desarrollo de una escala predictiva simple para la valoración pronóstica de pacientes COVID-19 en atención primaria**

**Resumen**

**Objetivo:** Investigar posibles factores pronósticos y escalas predictivas simples en adultos mayores con COVID-19.

**Diseño:** Cohorte retrospectiva de base comunitaria.

**Emplazamiento:** Atención Primaria Tarragona.

**Participantes:** 282 adultos ≥ 50 años no institucionalizados con COVID-19 confirmada (hospitalizada o ambulatoria) ocurrida durante marzo-junio de 2020.

**Mediciones principales:** La relación entre covariables basales (edad, sexo, condiciones/comorbilidades preexistentes y sintomatología inicial) y el riesgo de mala evolución (ingreso en UCI o muerte) se analizó mediante modelos de regresión logística.

**Resultados:** De los 282 casos de COVID-19 (edad media 65,9 años; 49,6% varones), 154 (54,6%) fueron hospitalizados (30 ingresados en UCI) y 45 (16%) fallecieron. En total, 64 (22,7%) requirieron UCI o fallecieron. La mediana de tiempo de seguimiento durante el curso clínico fue de 31 días (rango: 30-150) en los pacientes que sobrevivieron y de 14 días (rango: 1-81) en fallecidos. En análisis crudos, la edad/sexos, año varón, algunos comorbilidades (enfermedad renal, respiratoria o cardiaca, diabetes e hipertensión) y síntomas (confusión/letargia, disnea) se asociaron con mayor riesgo de UCI/muerte, mientras que otros síntomas (rinorrea, mialgias, cefalea, aguesia/anosmia) se asociaron con menor riesgo. En análisis multivariable solo la edad/sexos (OR: 1,04; IC 95%: 1,01-1,07; p = 0,004), confusión/letargia (OR: 5,33; IC 95%: 1,54-18,48; p = 0,008), disnea (OR: 5,41; IC 95%: 2,74-10,69; p = 0,001) y mialgias (OR: 0,30; IC 95%: 0,10-0,93; p = 0,038) permanecieron significativamente asociadas con mayor/menor riesgo. Una posible escala pronóstica CD65-M (acrónimo de las 4 variables mencionadas) mostró buena correlación con el riesgo de UCI/muerte (área bajo la curva ROC: 0,828; IC 95%: 0,774-0,882).

**Conclusión:** La evolución clínica en pacientes COVID-19 es inicialmente impredecible, pero la aplicación de escalas pronósticas simples como la propuesta CD65-M (pendiente de validación externa) podría ser útil para una orientación/valoración pronóstica de estos pacientes en atención primaria.

© 2021 Los Autores. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).

---

**Introduction**

The novel coronavirus SARS-COV-2 infection is causing the greatest infectious pandemic disease (COVID-19) in this century, with more than 60 million infected persons to date. Despite some time elapsed since pandemic started, population-based data about susceptibility and risk factors for COVID-19 is limited. There are numerous studies reporting clinical features and outcomes among hospitalised patients with severe COVID-19, but community- or population-based data including the overall spectrum of disease (i.e., patients with mild or moderate symptoms managed as outpatient or in ambulatory basis) is scarce.

It seems well established that the most severe and fatal cases, although they can occur in young and “healthy” people, are more frequent in older people and/or with comorbidities, like cardiovascular disease, hypertension, diabetes, chronic respiratory disease or chronic kidney disease. Smoking, obesity, male sex, socioeconomic deprivation and ethnicity were also associated with greater severity/lethality. In this sense, an ecological study in Barcelona reveals an inverse socioeconomic gradient in COVID-19 incidence. Lastly, multiple laboratory findings, viral and genetics factors may be associated with worse outcomes.

Several prognostic rules/algorithms have been reported by combining demographic, clinical, radiological and laboratory data. However, since a family physician point of view, the majority of predictive markers are not very useful in primary care settings because most of them requires radiological and/or analytical data few available in ambulatory basis.
This study investigated the possible relationship between pre-existing conditions/comorbidities and onset symptoms with the risk of suffering poor outcomes in a population-based cohort of community-dwelling middle-aged and older adults with symptomatic COVID-19 (including hospitalised and ambulatory cases) in the region of Tarragona (Spain). In addition, we explored and developed simple COVID-19 screening rules to predict critical outcomes (ICU admission or death) useful in outpatient settings.

Methods

Design, setting and study population

This is part of a large population-based retrospective-prospective cohort study (initiated in April 2020) involving 79,083 individuals in the region of Tarragona (Southern Catalonia, Spain). The design, setting and study population were extensively described in a prior article that evaluated the epidemiology of COVID-19 across the first wave of epidemic period in the study area.15 This report focuses on community-dwelling individuals 50 years or older, who had a laboratory-confirmed COVID-19 (hospitalised or outpatient) in the study setting between March 1st to June 30th, 2020. The study was approved by the Ethical Committee of the Institution (Ethics Committee IDIAP Jordi Gol, Barcelona, file 20/065-PCV) and was conducted in accordance with the general principles for observational studies.19 The study was determined to be exempt for informed consent under the public health surveillance exception.

Data sources

The pre-existing CAPAMIS Research Database, an institutional clinical research database previously used for other epidemiological cohort studies in the area,20 was updated for use as the main data source in this COVID-19 epidemiological investigation. Briefly, this research database compiles data from the institutional primary care clinical records electronic system (e-CAP), including administrative data and clinical information coded according to the International Classification of Diseases 10th Revision (ICD-10). It was used to identify sociodemographic characteristics and pre-existing conditions/comorbidities among cohort members and to establish their baseline characteristics at study start (01/03/2020).

When COVID-19 epidemic started, two electronic alerts including COVID-19’s laboratory registries plus ICD-10 codes for COVID-19 suspicion (B34.2, B97.29) were added to the e-CAP system and, later, both data sources were linked to construct the baseline research database used for the cohort study. In addition, in March 2020 a checklist of COVID-19 symptoms was quickly added to the e-CAP system to help family physicians in daily phone follow-up of COVID-19 patients. These electronic records, together complemented data registered during emergency visits and/or hospital-stay, were used to collect study data from patients. A trained research team of family physicians performed a retrospective review of the electronic health records to move the data to a standardised form, which was subsequently linked with the pre-existent main research database (which contained baseline characteristics of the 79,083 cohort members).

Outcome definitions

A confirmed COVID-19 case was defined when a cohort member tested positive in SARS-COV-2 RT-PCR (reverse transcription-polymerase chain reaction) or in serological testing, according institutional guidelines.21 A critical outcome was considered when the patient required ICU admission or died during clinical course. Death from COVID-19 was considered if the patient died from any cause within the first 30-day after the onset of the disease or in hospital-stay (any time).

Covariates

Apart from demographic characteristics and pre-existing conditions/comorbidities (see Appendix A), main covariates in this study were signs and symptoms of COVID-19 at presentation (within the first five days after the onset of illness). The check-listed symptoms (recruited according to data registered in the medical records, having been assessed by the attending physician in each case) were: cough, sore throat, rhinorrhea (including runny nose and/or nasal congestion), fatigue, myalgias, headache, anosmia, chest pain, dyspnoea (shortness of breath), vomiting/nausea, diarrhoea, confusion (including lethargy and/or delirium), general discomfort and fever (including low grade). A sign/symptom was considered absent if it was not recorded.

Statistical analysis

Descriptive statistics of sociodemographic and clinical variables included frequencies, percentages, means and standard deviations (SD). Comparison of differences between groups was performed using Chi-squared or Fisher test for categorical variables and Student’s t test for continuous variables.

Logistic regression analyses were performed to calculate the odds ratios (crude, age/sex-adjusted and multivariable-adjusted ORs) that assessed the relationship between demographic characteristics, pre-existing comorbidities and signs/symptoms of COVID19 at presentation with the risk of suffering a critical outcome (ICU/death) during the course of the disease.

The criteria used to construct potential prognostic rules predicting critical outcome are described below. Developed rules included those covariables that showed significant or nearly significant association (p < 0.10) with the dependent variable (ICU/death) in age/sex- and multivariable-adjusted logistic regression models. Discrimination and calibration were evaluated by means of receiver operating characteristic (ROC) curves, and the Hosmer–Lemeshow test, respectively. Sensitivity, specificity, positive and negative predictive values were calculated for distinct cut off points in the developed rules. In all analyses, statistical significance was set at p < 0.05 (two-tailed). The analyses were performed using IBM SPSS Statistics for Windows, version 24 (IBM Corp., Armonk, N.Y., USA).
Results

Of the 345 overall laboratory-confirmed COVID-19 cases observed in non-institutionalised cohort members across the study period, 63 were excluded from this analysis because non-available clinical data (n = 2), to be asymptomatic cases (n = 27) or to be considered nosocomial cases occurred inside social-health hospital stay (n = 34). Thus, the remaining 282 community-dwelling/non-institutionalised symptomatic COVID-19 cases were finally included in this report (see flow chart).

Mean age of cases was 65.9 years (SD: 12.1) and 140 (49.6%) were men. One hundred and fifty-four cases were hospitalised (30 of them were admitted in the ICU) and 128 were managed as outpatient (38 of them were attended in the emergency room but were not hospitalised). A total of 45 patients died (two in the emergency room before hospitalisation, 32 in hospital floor and 11 in the ICU). Overall, 64 (22.7%) suffered a critical outcome (ICU-admission or death). Median time follow-up in clinical course was 31 days (range: 30–150) for survivors and 14 days (range: 1–81) for deceased patients.

The most prevalent comorbidities were hypertension (42.6%), obesity (25.5%), cardiac disease (23.4%), diabetes (19.1%) and respiratory disease (17.4%).

The most common signs/symptoms at COVID-19 presentation (first 5 days after onset of symptoms or medical contact) were fever (70.9%) and cough (67.7%) followed by general discomfort (42.2%), dyspnoea (39.7%), fatigue (30.1%), myalgias (27.3%), diarrhoea (24.1%) and headache (23%).

Table 1 compares demographic and clinical characteristics of cases according if they presented or not a critical outcome. Patients who suffered a critical outcome were older (mean age 73.6 vs 63.7 years, p < 0.001) and had more comorbidities (2.6 vs 1.5 comorbidities, p < 0.001) than those who did not suffer a critical outcome.

In the crude analyses several pre-existing conditions/comorbidities (renal, respiratory, cardiac disease, diabetes and hypertension) and two symptoms (dyspnoea and confusion) were significantly associated with a greater risk of admission to the ICU/death, whereas other symptoms (myalgias, headache and anosmia) were associated with a reduced risk. After age and sex-adjustment, apart from increasing age/years (OR: 1.07) and amile sex (OR: 1.64), only chronic respiratory disease (OR: 2.20) and diabetes (OR: 1.89), dyspnoea (OR: 5.30) and confusion (OR: 4.95) remained significantly (or nearly significantly) associated with an increased risk, whereas myalgias (OR: 0.27) and the cluster symptom combining ageusia/anosmia/rinorhrea (OR: 0.36) were associated with a significant reduced risk (Table 2).

Finally, after multivariable-adjustment only age/years (OR: 1.04; 95% CI: 1.01–1.07; p = 0.004), confusion (OR: 5.33; 95% CI: 1.54–18.48; p = 0.008), dyspnoea (OR: 5.41; 95% CI: 2.74–10.69; p < 0.001) and myalgias (OR: 0.30; 95% CI: 0.10–0.93; p = 0.038) remained significantly associated with increased or reduced risk of suffering a critical outcome (Table 3). In alternative analyses by Cox regression models the results were essentially similar, being age, confusion, dyspnoea and myalgias the unique variables significantly associated with a greater/lower risk for critical outcome (see Table S1 in supplementary material).

We used this multivariable-adjusted model to develop a simple predictive prognostic rule, named CD65-M (acronym for Confusion, Dyspnoea, and Age > 65 years, which contributed with a positive point each; and Myalgias which contributed with a negative point in the score), that showed an acceptable correlation with the risk of suffering a critical outcome (area under ROC curve: 0.828; 95% CI: 0.774–0.882).

Additionally, by using the logistic regression model adjusted by age and sex (Table 2) we explored and developed a larger predictive rule including the 8 significant variables in that model. According to magnitude changes in the ORs, this rule called CD65RD-WMA (acronym of the initials of the names of the 8 included variables) weights 2 points for each one of Confusion and Dyspnoea, 2 points for age greater than 80 years and one point for age between 65 and 79 years, one point for Respiratory disease and other for Diabetes. Furthermore, the score weights a negative point for each one of the following: Women, Myalgias and combined Ageusia/anosmia/rinorhrea.

This longest CD65RD-WMA score (which may vary between 3 and 8 points) also showed a good correlation with the probability of suffering a critical outcome during clinical course, but did not substantially increased discriminatory power (area under ROC curve: 0.836; 95% CI: 0.784–0.889)

Fig. 1 compares ROC curves for both CD65 and CD65RD-WMA rules.

Table 4 shows the absolute numbers and percentages of observed cases and critical outcomes in each scoring for both simple and longer rules.

Sensitivity, specificity, positive and negative predictive values for different cut off points in both rules are shown in Table 5.

Discussion

In the current context of global pandemic and public health emergency by COVID-19, the knowledge of protective and/or risk factors to suffer infection or develop poor outcomes is essential for adequate management of patients in earlier stages of the disease.17 In the present community-based cohort study, apart from increasing age that has repeatedly documented as major risk condition,16-18 we have also found that some early symptoms (within the first five days after the onset of disease) are associated with better or poor prognosis (i.e., need of ICU admission or death). Indeed, presence of dyspnoea and confusion clearly increased the risk of ICU-admission or death, whereas myalgia was associated with a reduced risk.

On the first, it is not surprising since both variables, or related-variables, were already associated with an increased risk of death in patients with community-acquired pneumonia, having been already included confusion and tachypnea as predictor variables within simple prognostic rules (such as CURB-65 or CRB-65 rules) assessing severity in patients with pneumonia.21-24

On the second, surprisingly, myalgias emerged independently associated with a reduced risk for critical outcomes after multivariable adjustments. This may be considered as an unexpected result, but we note that it is not unique
Table 1  Univariate analyses comparing characteristics (demographics, pre-existing comorbidities and early symptoms at presentation) in 282 community-dwelling COVID-19 patients over 50 years according to occurrence or not of a critical outcome (ICU-admission or death) across clinical course.

| Variable                  | Non-ICU/death (N=218) | ICU/death (N=64) | p-value | Total (N=282) |
|---------------------------|------------------------|------------------|---------|---------------|
|                           | n (%)                  | n (%)            |         | n (%)         |
| **Demographics**          |                        |                  |         |               |
| Age: 50–64 yrs            | 142 (65.1)             | 13 (20.3)        | <0.001  | 155 (54.9)    |
| 65–79 yrs                 | 56 (25.7)              | 31 (48.4)        |         | 87 (30.9)     |
| ≥80 yrs                   | 20 (9.2)               | 20 (31.3)        |         | 40 (14.2)     |
| Sex: Men                  | 101 (46.3)             | 39 (60.9)        | 0.040   | 140 (49.6)    |
| Women                     | 117 (53.7)             | 25 (39.1)        |         | 142 (50.4)    |
| **Comorbidities**         |                        |                  |         |               |
| Neurological              | 4 (1.8)                | 4 (6.3)          | 0.061   | 8 (2.8)       |
| Renal                     | 18 (8.3)               | 11 (17.2)        | 0.039   | 29 (10.3)     |
| Cancer                    | 24 (11.0)              | 10 (15.6)        | 0.319   | 34 (12.1)     |
| Rheumatic                 | 4 (1.8)                | 1 (1.6)          | 0.885   | 5 (1.8)       |
| Respiratory               | 28 (12.8)              | 21 (32.8)        | <0.001  | 49 (17.4)     |
| Cardiac                   | 43 (19.7)              | 23 (35.9)        | 0.007   | 66 (23.4)     |
| Atrial fibrillation       | 16 (7.3)               | 9 (14.1)         | 0.096   | 25 (8.9)      |
| Liver disease             | 3 (1.4)                | 3 (4.7)          | 0.107   | 6 (2.1)       |
| Hypertension              | 83 (38.1)              | 37 (57.8)        | 0.005   | 120 (42.6)    |
| Diabetes                  | 31 (14.2)              | 23 (35.9)        | <0.001  | 54 (19.1)     |
| Smoking                   | 21 (9.6)               | 4 (6.3)          | 0.402   | 25 (8.9)      |
| Alcoholism                | 5 (2.3)                | 2 (3.1)          | 0.707   | 7 (2.5)       |
| Obesity                   | 54 (24.8)              | 18 (28.1)        | 0.588   | 72 (25.5)     |
| **Symptoms**              |                        |                  |         |               |
| Cough                     | 153 (70.2)             | 38 (59.4)        | 0.104   | 191 (67.7)    |
| Sore throat               | 31 (14.2)              | 6 (9.4)          | 0.313   | 37 (13.1)     |
| Rinorhrea (RN)            | 26 (11.9)              | 2 (3.1)          | 0.038   | 28 (9.9)      |
| Myalgias                  | 73 (33.5)              | 4 (6.3)          | <0.001  | 77 (27.3)     |
| Fatigue                   | 67 (30.7)              | 18 (28.1)        | 0.689   | 85 (30.1)     |
| Headache                  | 53 (24.3)              | 6 (9.4)          | 0.010   | 59 (20.9)     |
| Ageusia/disgeusia         | 28 (12.8)              | 3 (4.7)          | 0.067   | 31 (11.0)     |
| (AG)                      |                        |                  |         |               |
| Anosmia (AN)              | 34 (15.6)              | 3 (4.7)          | 0.023   | 37 (13.1)     |
| Cluster RN/AG/AN          | 61 (28.0)              | 4 (6.3)          | <0.001  | 65 (23.0)     |
| Chest pain                | 31 (14.2)              | 6 (9.4)          | 0.313   | 37 (13.1)     |
| Dyspnoea                  | 65 (29.8)              | 47 (73.4)        | <0.001  | 112 (39.7)    |
| Vomiting                  | 12 (5.5)               | 3 (4.7)          | 0.798   | 15 (5.3)      |
| Diarrhoea                 | 53 (24.3)              | 15 (23.4)        | 0.886   | 68 (24.1)     |
| Confusion                 | 5 (2.3)                | 10 (15.6)        | <0.001  | 15 (5.3)      |
| General discomfort        | 93 (42.7)              | 26 (40.6)        | 0.772   | 119 (42.2)    |
| Fever                     | 154 (70.6)             | 46 (71.9)        | 0.849   | 200 (70.9)    |

NOTE: Early symptoms were considered within the first five days of the onset of disease. p-values were calculated by using chi-squared or Fisher’s test as appropriate.

and has already been reported by other studies. Concretely, in a single-centre French cohort study that included 150 hospitalised COVID-19 consecutive patients between March-April 2020, the percentage of cases who had myalgia was significantly greater among those patients with favourable clinical course than in those who required ICU-admission or died.16 We have not a physiopathological explanation for this unexpected finding. We recognise its scarce biological plausibility and, therefore, a simple statistical association may not be fully excluded. Few studies have considered myalgias as independents symptom in COVID19 patients. A study considering 6 different cluster of symptoms found that myalgia associated with dyspnoea/shortness of breath and confusion was associated with more need of respiratory support, but if it is included within a cluster symptoms called “influenza-like” (without respiratory or neurological symptoms) myalgia was associated with a lower need of respiratory support.25
Table 2  Logistic regression analyses estimating crude and age/sex-adjusted odds ratios (ORs) to evaluate risks of suffering a critical outcome (ICU/death) by age, sex, pre-existing comorbidities and early symptoms in the 282 COVID-19 study subjects.

| Variable                      | Unadjusted OR (95% CI) p | Adjusted OR (95% CI) p |
|-------------------------------|--------------------------|------------------------|
| **Demographics**              |                          |                        |
| Age, continuous yrs           | 1.07 (1.05–1.10) <0.001  | 1.07 (1.05–1.10) <0.001 |
| Age group: 50–64 yrs          | 1.00 (reference) <0.001  | 1.00 (reference) <0.001 |
| 65–79 yrs                     | 6.05 (2.95–12.39) <0.001 | 5.74 (2.79–11.82) <0.001 |
| ≥80 yrs                       | 10.92 (4.71–25.32) <0.001| 10.59 (4.55–24.62) <0.001|
| Sex male                      | 1.81 (1.02–3.19) 0.041   | 1.69 (0.92–3.11) 0.089  |
| **Comorbidities**             |                          |                        |
| Neurological                  | 3.57 (0.87–14.69) 0.078  | 1.91 (0.41–8.91) 0.411  |
| Renal                         | 2.31 (1.03–5.18) 0.043   | 1.05 (0.43–2.61) 0.912  |
| Cancer                        | 1.50 (0.68–3.32) 0.321   | 0.92 (0.38–2.19) 0.845  |
| Rheumatic                     | 0.85 (0.09–7.74) 0.885   | 0.78 (0.08–7.75) 0.830  |
| Respiratory                   | 3.31 (1.72–6.38) <0.001  | 2.20 (1.09–4.44) 0.028  |
| Cardiac                       | 2.28 (1.24–4.20) 0.008   | 1.11 (0.56–2.22) 0.762  |
| Atrial fibrillation           | 2.07 (0.87–4.93) 0.102   | 0.83 (0.32–2.19) 0.712  |
| Liver disease                 | 3.53 (0.69–17.91) 0.129  | 2.43 (0.43–13.62) 0.312 |
| Diabetes                      | 3.38 (1.79–6.40) <0.001  | 1.89 (0.94–3.78) 0.073  |
| Hypertension                  | 2.23 (1.27–3.93) 0.006   | 1.06 (0.55–2.06) 0.855  |
| Smoking                       | 0.63 (0.21–1.89) 0.406   | 0.70 (0.21–2.33) 0.559  |
| Alcoholism                     | 1.37 (0.26–7.26) 0.708   | 1.28 (0.22–7.60) 0.784  |
| Obesity                       | 1.19 (0.64–2.22) 0.589   | 1.02 (0.52–2.00) 0.951  |
| **Symptoms**                  |                          |                        |
| Cough                         | 0.62 (0.35–1.11) 0.106   | 0.68 (0.37–1.28) 0.234  |
| Sore throat                   | 0.62 (0.25–1.57) 0.316   | 0.79 (0.30–2.08) 0.634  |
| Rinorhrea (RN)                | 0.24 (0.06–1.03) 0.055   | 0.44 (0.10–1.97) 0.280  |
| Myalgias                      | 0.13 (0.05–0.38) <0.001  | 0.27 (0.09–0.81) 0.020  |
| Fatigue                       | 0.88 (0.48–1.63) 0.689   | 1.03 (0.53–2.00) 0.931  |
| Headache                      | 0.32 (0.13–0.79) 0.013   | 0.61 (0.24–1.60) 0.316  |
| Ageusia/disgeusia (AG)        | 0.33 (0.10–1.14) 0.079   | 0.83 (0.22–3.08) 0.781  |
| Anosmia (AN)                  | 0.27 (0.08–0.90) 0.033   | 0.74 (0.20–2.72) 0.649  |
| Cluster AN/AG/RN              | 0.17 (0.06–0.49) 0.001   | 0.36 (0.12–1.09) 0.070  |
| Chest pain                    | 0.62 (0.25–1.57) 0.316   | 0.69 (0.26–1.85) 0.464  |
| Dyspnoea                      | 6.51 (3.48–12.17) <0.001 | 5.30 (2.75–10.24) <0.001|
| Vomiting                      | 0.84 (0.23–3.09) 0.798   | 0.90 (0.23–3.59) 0.886  |
| Diarrhoea                     | 0.95 (0.50–1.84) 0.886   | 1.14 (0.56–2.31) 0.713  |
| Confusion                     | 7.89 (2.59–24.04) <0.001 | 4.95 (1.49–16.43) 0.009|
| General discomfort            | 0.92 (0.52–1.62) 0.772   | 0.93 (0.51–1.70) 0.804  |
| Fever                         | 1.06 (0.57–1.97) 0.849   | 1.20 (0.62–2.36) 0.587  |

NOTE: Odds ratios were calculated for those who had the condition as compared with those who had not it.

Table 3  Multivariable logistic regression model assessing risk of suffering a critical outcome (ICU-admission or death) among the 282 COVID-19 study subjects.

| Variable          | Odds ratio   | (95% CI)    | p value |
|-------------------|--------------|-------------|---------|
| Age (continuous yrs) | 1.04        | (1.01–1.07) | 0.004   |
| Dyspnoea          | 5.41         | (2.74–10.69)| <0.001  |
| Confusion         | 5.33         | (1.54–18.48)| 0.008   |
| Myalgias          | 0.30         | (0.10–0.93) | 0.038   |

NOTE: Odds ratios were calculated for those who had the condition as compared with those who had not it. The Hosmer and Lemeshow test (Chi-square = 5683, with 8 df) was not significant (p = 0.683), indicating a good calibration of the model.
showed a point above respectively.

Table 4 Distribution of overall COVID-19 cases and observed critical outcomes (ICU-admission or death) according to distinct scoring strata for both the simple CD65-M and the longer CD65RD-WMA prognostic rules.

| Score  | Overall cases | Critical outcomes |
|--------|---------------|------------------|
|        | N = 282       | (ICU-admission or death) |
|        | n (%)        | n (%)            |
| Cd65RD-Wma |
| –3     | 18 (6.4)      | 0 (–)             |
| –2     | 31 (11.0)     | 1 (3.2)           |
| –1     | 49 (17.4)     | 1 (2.0)           |
| 0      | 40 (14.2)     | 5 (12.5)          |
| 1      | 34 (12.1)     | 6 (17.6)          |
| 2      | 34 (12.1)     | 9 (26.5)          |
| 3      | 33 (11.7)     | 15 (45.5)         |
| 4      | 19 (6.7)      | 12 (63.2)         |
| 5      | 17 (6.0)      | 9 (52.9)          |
| 6      | 6 (2.1)       | 5 (83.3)          |
| 7      | 1 (0.4)       | 1 (100)           |

CD65-M

|       | Overall cases | Critical outcomes |
|-------|---------------|------------------|
|       | N = 282       | (ICU-admission or death) |
|       | n (%)        | n (%)            |
| –1    | 51 (18.1)     | 1 (2.0)           |
| 0     | 82 (29.1)     | 4 (4.9)           |
| 1     | 76 (27.0)     | 18 (23.7)         |
| 2     | 67 (23.8)     | 36 (53.7)         |
| 3     | 6 (2.1)       | 5 (83.3)          |

a The percentage indicates number of COVID-19 cases in each scoring strata divided by the total COVID-19 cases.
b The percentage indicates the number of critical outcome (ICU/death) observed in each scoring strata divided by the overall COVID-19 cases in that scoring strata.

Figure 1 Comparison of ROC curves for both simple CD65-M and longer CD65RD-WMA rules.

We constructed a simple prognostic rule containing the above mentioned four variables (CD65-M score), which showed a good correlation with the probability of suffering a critical outcome across clinical course, being 2%, 4.9%, 23.7%, 53.7% and 83.3% for scoring –1, 0, 1, 2 and 3, respectively. According this CD65-M rule, the best cut-off point for predicting bad evolution would be scoring ≥1 (92% sensitivity with 59% specificity) or scoring ≥2 (64% sensitivity with 85% specificity).

If we consider pre-existing comorbidities, many studies have reported increased risk of poor outcomes among patients with diverse comorbidities (especially cardiac, respiratory or renal disease, diabetes, obesity and hypertension), but most studies assessed crude associations (without age- and/or multivariable-adjusted risk). 5,8,20-29

In the present study we also observed these associations in the crude analyses, but after multivariable adjustment none pre-existing comorbidity was associated with an adjusted increased risk in our study population.

Nevertheless, since respiratory disease and diabetes were significantly associated with an increased risk in the age and sex-adjusted model, we explored and developed a second lengthy rule (CD65RD-WMA) including significant variables in that model. However, this second model did not substantially improve predictive performance of the first simpler CD65-M rule (containing exclusively the 4 significant predictor variables after multivariable-adjustment).

Main strengths in this study were its population-based design (including as hospitalised as well as ambulatory COVID-19 cases), the assessment of early COVID-19 symptoms as possible predictors (rare in the literature), and the large follow-up necessary to adequately recruit the occurrence of critical outcomes during the clinical course (i.e., deaths occurred in hospitalised COVID-19 patients several weeks after hospital or ICU admission). In addition, we performed multivariable-adjusted analysis to accurately estimate relationships between baseline covariables and risk of suffering a critical outcome, developing simple predictive prognostic rules (which may be especially useful in primary
Table 5  Sensitivity, specificity, positive and negative predictive values observed in the study population according to different cut off points for the CD65RD-WMA and CD65-M scores.

| Cut-off scoring | Sensitivity % (95% CI) | Specificity % (95% CI) | Positive PV % (95% CI) | Negative PV % (95% CI) |
|-----------------|------------------------|------------------------|------------------------|------------------------|
| **CD65RD-WMA**  |                        |                        |                        |                        |
| 0 or less       | 97 (89-99)             | 54 (47-61)             | 74 (64-82)             | 98 (93-99)             |
| ≥1              | 89 (79-95)             | 60 (53-66)             | 40 (32-48)             | 95 (90-98)             |
| ≥2              | 80 (68-88)             | 73 (67-78)             | 46 (37-56)             | 92 (88-96)             |
| ≥3              | 66 (53-76)             | 84 (79-89)             | 55 (44-66)             | 89 (84-93)             |
| ≥4              | 42 (31-54)             | 93 (88-95)             | 63 (48-76)             | 85 (79-89)             |
| ≥5              | 23 (15-35)             | 96 (92-98)             | 63 (43-79)             | 81 (76-85)             |
| **CD65-M**      |                        |                        |                        |                        |
| 0 or less       | 98 (92-100)            | 23 (18-29)             | 27 (22-33)             | 98 (90-100)            |
| ≥1              | 92 (83-97)             | 59 (52-65)             | 40 (32-48)             | 96 (92-98)             |
| ≥2              | 64 (52-75)             | 85 (80-89)             | 56 (45-67)             | 89 (84-93)             |
| 3               | 8 (3-17)               | 100 (97-100)           | 83 (44-97)             | 79 (73-83)             |

Note: PV means predictive value; CI denotes confidence interval.

care settings). The observed prevalence for most symptoms fits with data reported in other epidemiological studies, which supports the validity of collected data despite retrospective design.

As major limitations, our study was conducted in a single geographical area with specific epidemic conditions (relatively low incidence of COVID-19) in a limited time period (first wave of pandemic) and focused exclusively on community-dwelling people over 50 years. We do not know the possible influence that changes in study population and/or epidemic intensity could have on the statistics reported here. We also note that the relatively little sample size (282 cases with 64 outcomes in our study) building prediction models may increase the risk of overfitting the model, which implies that the performances of the models in new samples could be worse. We underline that a further validation in an external cohort is necessary before a routine use of the described prognostic rules may be applied. We note, however, that prediction models are needed to support medical decision managing COVID-19 patients.

There are several published or preprint reports that developed prognostic rules predicting critical outcomes (need of mechanical ventilation and/or death), but all of them were based on complementary explorations or laboratory findings which are not generally available in ambulatory or primary care settings. Main contribution of this study lies in the fact that it reports simple clinical prognostic rules including easily accessible clinical data (such as demographics, pre-existing comorbidities and early symptomatology), which could be very helpful assessing COVID-19 patients outside the hospital.

We conclude that the clinical course of COVID-19 patients remains unpredictable in earlier stages of the disease, but simple clinical tools as the proposed CD65-M prognostic rule (pending external validation) may be helpful assessing these patients in primary care settings. Further evaluations adding other easily accessible complementary data (e.g., pulse-oximetry to detect silent hypoxia) could improve predictive performance.

Keypoints

What is already known on this concern

- COVID-19 may occur with heterogeneous symptomatology and diverse clinical course.
- It is believed that clinical course of COVID-19 cannot be predicted in early stages of the disease.
- Predictive prognostic rules useful in primary care settings have not been developed to date.

What this study adds

- This study evaluates relationship between baseline pre-existing conditions and early symptomatology with the risk to suffer a critical outcome during clinical course (ICU-admission or death) among community-dwelling middle-aged and older adults.
- In the crude analyses, increasing age, sex men, several pre-existing conditions (chronic renal, respiratory or cardiac disease, diabetes and hypertension) and some symptoms (dyspnoea, confusion) were associated with increasing risk while other symptoms (nasal congestion, myalgias, headache and anosmia) were related with a reduced risk for critical outcome.
- After multivariable-adjustment, only age/years, dyspnoea and confusion remained independently associated with an increased risk whereas myalgia was associated with a reduced risk.

Contributors

AVC designed the study; AVC and ESG assessed outcomes and wrote the manuscript; ESG, CDC and MFP obtained data; ESG and AVR did statistical analyses and edited the manuscript; OOG revised the final version; AVC coordinated the study.
Conflict of interest

None declared.

Funding

This study is supported by grants from “Fundació Hospital Joan XXIII (Tarragona)” and from the Instituto de Salud Carlos III of the Spanish Health Ministry (file COV20/00852; call for the SARS-COV-2/COVID-19 disease, RDL 8/2020, March 17, 2020). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Appendix A. Criteria used to identify pre-existing conditions/comorbidities in the study population.

| Comorbidities with ICD-10 codes [International Classification of Diseases, 10th Revision] |
|-----------------------------------------------|
| **Neurological disease**                      |
| Dementia                                       | F01–F03 |
| Ictus                                          | I63, I61 |
| Chronic renal failure                          | N18–N19 |
| Cancer (solid organ or haematological neoplasia) in past 5 years | C00–C97 |
| Rheumatologic disease                         |         |
| Rheumatoid arthritis, enteropathic arthritis   | M05–M09 |
| Arthropathies and juvenile arthritis           |         |
| Systemic lupus erythematosus                   | M32     |
| **Chronic pulmonary/respiratory disease**     |
| Chronic bronchitis/emphysema                   | J41–J44 |
| Asthma                                         | J45–J46 |
| Other chronic pulmonary diseases               | P27, E84, J47 |
| **Chronic heart disease**                     |
| Congestive heart failure                       | I50     |
| Coronary artery disease                        | I20–I22, I25 |
| Other chronic heart diseases                   | I05–I08, I11, I35–I37, I42, I51.7 |
| **Atrial fibrillation**                        |
| I48                                            |
| **Chronic liver disease**                     |
| Chronic viral hepatitis                        | B18     |
| Cirrhosis                                      | K74     |
| Alcoholic hepatitis                            | K70     |
| **Diabetes mellitus**                          |
| E10–E14                                        |
| **Hypertension**                               |
| I10, I11, I12 or I15                           |
| **Hypercholesterolemia**                      |
| E78                                            |
| **Obesity**                                    |
| E66                                            |
| **Smoking**                                    |
| F17                                            |

Appendix B. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.aprim.2021.102118.
16. Allenbach Y, Saadoun D, Maalouf G, Vieira M, Hellow A, Bod-daert J, et al. Development of a multivariate prediction model of intensive care unit transfer or death: A French prospective cohort study of hospitalised COVID-19 patients. PLOS ONE. 2020;15:e0240711.

17. Wynants L, Van Calster B, Collins GS, Riley RD, Heinzé G, Schuit E, et al. Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal [published correction appears in BMJ. 2020 Jun 3;369:m2204]. BMJ. 2020;369:m1328.

18. Vila-Corcoles A, Ochoa-Gondar O, Satue-Gracia EM, Torrente-Fraga C, Gomez-Bertomeu F, Vila-Rovira A, et al. Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona, Spain. BMJ Open. 2020;10:e041577, https://dx.doi.org/10.1136/bmjopen-2020-041577.

19. World Medical Association. WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. Available at: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ [Accessed 14 May 2020].

20. Vila-Corcoles A, Hospital-Guardiola I, Ochoa-Gondar O, De Diego C, Salenç C, Raga X, et al. Rationale and design of the CAPANS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke. BMC Public Health. 2010;10:25.

21. Generalitat de Catalunya. Sub-direcció General de Vigilància i Resposta a Emergències de Salut Pública. Procediment d’actuació enfront de casos d’infecció pel nou coronavirus SARS-CoV-2. Available at: https://canalsalut.gencat.cat/web/.content/A-Z/C/coronavirus-2019-ncov/material-divulgatiu/procediment-actuacio-coronavirus.pdf [Accessed 16 May 2020].

22. Lim WS, Van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI. Defining acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–82.

23. Myint PK, Kamath AV, Vowler SL, Maisey DN, Harrison BD. The CURB (confusion, urea, respiratory rate and blood pressure) criteria in community acquired pneumonia (CAP) in hospitalised elderly patients aged 65 years and over: a prospective observational cohort study. Age Ageing. 2005;34:75–7.

24. Bont J, Hak E, Hoes AW, Macfarlane JT, Verheij TJ. Predicting death in elderly patients with community-acquired pneumonia: a prospective validation study reevaluating the CRB-65 severity assessment tool. Arch Intern Med. 2008;168:1465–8.

25. Sudre CH, Lee KA, Lochlann MN, Varsavsky T, Murray B, Graham M, et al. Symptom clusters in COVID-19: A potential clinical prediction tool from the COVID Symptom Study app. Sci Adv. 2021;7, eabd4177.

26. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.

27. de Lusignan S, Dorward J, Correa A, Jones N, Akinyemi O, Amirthalingam G, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis. 2020;20:1034–42.

28. Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Crit Care. 2020;24:179.

29. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvats K, Marelli-Berg FM, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116:1666–87.

30. Grant MC, Geoghegan L, Arby M, Mohammed Z, McGuinness L, Clarke EL, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries. PLOS ONE. 2020;15, e0234765.